MedPath

Effect of Oxidized Plant Sterols on Serum Concentrations of Plant Sterol Oxidation Products (POP)

Not Applicable
Completed
Conditions
Healthy
Interventions
Other: cookies enriched with POP
Registration Number
NCT03312816
Lead Sponsor
Unilever R&D
Brief Summary

The study is a randomised, double-blind, placebocontrolled, parallel dose-response study with four study arms. Sixty subjects will be randomly allocated to consume study products containing varying amounts of plant sterol (PS) oxidation products (POP) or placebo for 6 weeks.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Apparently healthy men and women as judged by study physician.
  • BMI > 18 and < 35 kg/m2.
  • Total cholesterol levels at screening ≥5.0 and ≤8.0 mmol/L
  • Blood pressure, heart rate, haematological and clinical chemical parameters within the normal reference range as judged by the study physician.
Exclusion Criteria
  • Recently (<6 months) diagnosed with cardiovascular event(s) (stroke, TIA (Transient ischemic attack), angina, myocardial infarction, heart failure), revascularization or systemic inflammatory conditions.
  • Use of plant-sterol/stanol-enriched foods or supplements in the three months prior to the screening and/or during the study.
  • Use of over-the-counter and prescribed medication which may interfere with study measurements (i.e. statins, ezetimibe, fibrates, diabetic drugs, angiotensin receptor blockers (ARB) and ACE (Angiotensin-converting enzyme) inhibitors)), to be judged by the principal investigator.
  • Use of oral antibiotics (with the exception of topical antibiotics) in 40 days or less prior to Day -2.
  • Pregnant or lactating women.
  • Reported alcohol consumption > 14 units/week (female) or > 21 units/week (male).
  • Reported intense sporting activities > 10 hours/week.
  • Reported weight loss or gain of 3 kg or more during a period of 6 months prior to screening.
  • Currently on a medically- or self-prescribed diet, or slimming diet, or the intention to use any kind of diet during the study.
  • Currently smoking or being a non-smoker for less than 6 months and reported use of any nicotine containing products in the 6 months prior to screening and/or during the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
low dosagecookies enriched with POPlow added POP
Medium dosecookies enriched with POPmedium added POP
Placebocookies enriched with POP0 mg/d added POP
Hige dosecookies enriched with POPhigh added POP
Primary Outcome Measures
NameTimeMethod
POP (plant sterol oxidation products) value0 to 42 days

To estimate the change from baseline in serum POP concentration after intake of various POP doses.

Secondary Outcome Measures
NameTimeMethod
Ratio of serum POP concentration0 to 42 days

To estimate the ratio of serum POP concentrations vs. COP concentrations after intake of various POP doses.

COP (cholesterol oxidation products) value0 to 42 days

To estimate the change from baseline in serum COP concentrations after intake of various POP doses.

Trial Locations

Locations (1)

Charité Research Organisation GmbH

🇩🇪

Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath